Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emi Yamazaki

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Dermatology|December 26, 2025
Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced PatientsToshiki Okazaki, Takehiro Takahashi, Moyuka Wada-Irimada, et al.
The Journal of Dermatology|March 25, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.
The Journal of Dermatology|April 17, 2024
Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
Journal of Clinical Medicine|September 28, 2024
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective StudySaki Okuda-Hiwatashi, Ryo Amagai, Taku Fujimura, et al.
Journal of Clinical Medicine|February 26, 2025
An Evaluation of Prognostic Factors in Cutaneous Squamous Cell Carcinoma: A Single-Center Study of 237 Japanese CasesEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.
The Journal of Dermatology|June 20, 2025
Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single InstituteMoyuka Wada-Irimada, Takehiro Takahashi, Mana Sekine, et al.
The Journal of Dermatology|January 27, 2025
Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single centerMoyuka Wada-Irimada, Takehiro Takahashi, Mana Sekine, et al.
Case Reports in Oncology|July 10, 2025
A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up CaseMoyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, et al.
Case Reports in Oncology|October 30, 2024
Successful Treatment of Unresectable <i>BRCA1</i> L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case ReportSaaya Yoshida-Akai, Taku Fujimura, Ryo Amagai, et al.
The British Journal of Dermatology|June 4, 2024
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trialTaku Fujimura, Koji Yoshino, Hiroshi Kato, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Dermatology|December 26, 2025
Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced PatientsToshiki Okazaki, Takehiro Takahashi, Moyuka Wada-Irimada, et al.
The Journal of Dermatology|March 25, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatmentRyo Amagai, Taku Fujimura, Yumi Kambayashi, et al.
The Journal of Dermatology|April 17, 2024
Radiation-induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case reportManami Takahashi-Watanabe, Taku Fujimura, Ryo Amagai, et al.
Journal of Clinical Medicine|September 28, 2024
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective StudySaki Okuda-Hiwatashi, Ryo Amagai, Taku Fujimura, et al.
Journal of Clinical Medicine|February 26, 2025
An Evaluation of Prognostic Factors in Cutaneous Squamous Cell Carcinoma: A Single-Center Study of 237 Japanese CasesEmi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, et al.
The Journal of Dermatology|June 20, 2025
Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single InstituteMoyuka Wada-Irimada, Takehiro Takahashi, Mana Sekine, et al.
The Journal of Dermatology|January 27, 2025
Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single centerMoyuka Wada-Irimada, Takehiro Takahashi, Mana Sekine, et al.
Case Reports in Oncology|July 10, 2025
A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up CaseMoyuka Wada-Irimada, Taku Fujimura, Manami Takahashi-Watanabe, et al.
Case Reports in Oncology|October 30, 2024
Successful Treatment of Unresectable <i>BRCA1</i> L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case ReportSaaya Yoshida-Akai, Taku Fujimura, Ryo Amagai, et al.
The British Journal of Dermatology|June 4, 2024
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trialTaku Fujimura, Koji Yoshino, Hiroshi Kato, et al.
Pageof 4